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Abstract
Background: Regimens for isoniazid-based preventive therapy (IPT) for tuberculosis (TB) in HIV-infected individuals have not
been widely adopted given concerns regarding efficacy, adherence and drug resistance. Further, the cost-effectiveness of
IPT has not been studied in India.
Methods: We used an HIV/TB model to project TB incidence, life expectancy, cost and incremental cost-effectiveness of six
months of isoniazid plus ethambutol (6EH), thirty-six months of isoniazid (36H) and no IPT for HIV-infected patients in India.
Model input parameters included a median CD4 count of 324 cells/mm
3, and a rate ratio of developing TB of 0.35 for 6EH
and 0.22 for 36H at three years as compared to no IPT. Results of 6EH and 36H were also compared to six months of
isoniazid (6H), three months of isoniazid plus rifampin (3RH) and three months of isoniazid plus rifapentine (3RPTH).
Results: Projected TB incidence decreased in the 6EH and 36H regimens by 51% and 62% respectively at three-year follow-
up compared to no IPT. Without IPT, projected life expectancy was 136.1 months at a lifetime per person cost of $5,630. 6EH
increased life expectancy by 0.8 months at an additional per person cost of $100 (incremental cost-effectiveness ratio (ICER)
of $1,490/year of life saved (YLS)). 36H further increased life expectancy by 0.2 months with an additional per person cost of
$55 (ICER of $3,120/YLS). The projected clinical impact of 6EH was comparable to 6H and 3RH; however when compared to
these other options, 6EH was no longer cost-effective given the high cost of ethambutol. Results were sensitive to baseline
CD4 count and adherence.
Conclusions: Three, six and thirty-six-month regimens of isoniazid-based therapy are effective in preventing TB. Three
months of isoniazid plus rifampin and six-months of isoniazid are similarly cost-effective in India, and should be considered
part of HIV care.
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Introduction
The HIV and tuberculosis epidemics represent a major public
health challenge in India [1,2]. Among the estimated 2.4 million
people living with HIV/AIDS in India, the incidence of active TB
has been reported as high as 6.90 cases/100 person-years (PY)
[3,4]. This is driven in part by reactivation disease in the estimated
40% of HIV-infected persons latently infected with TB [5].
Given the challenge of controlling these epidemics, major
stakeholders convened at the World Health Organization and
identified intensified TB case-finding, infection control, and
isoniazid-based preventive therapy (IPT) as crucial measures in
reducing the impact of TB on people living with HIV [6]. In
India’s governmental response to the epidemics, the Central TB
Division (CTD) and National AIDS Control Organisation
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e36001(NACO) initiated an ‘‘intensified TB-HIV package’’ of services
including routine HIV testing for TB patients and enhanced TB
monitoring [7]. While IPT was not recommended, the cost-
effectiveness of IPT was listed as a priority research area [7]. Our
objective was to examine the cost-effectiveness of IPT for HIV-
infected patients in India.
Methods
Analytic Overview
We incorporated data from the National Institute for Research
in Tuberculosis clinical trial entitled ‘‘Preventive Therapy for TB
in HIV-Infected Patients’’ in India into a previously published
model of HIV/TB disease to project the long-term clinical and
economic impact of alternative strategies of IPT [8,9,10,11]. The
internal validity of the model was assessed by comparing projected
incidence of active TB in the IPT strategies at three years to
outcomes of the trial [9]. Model outcomes included the incidence
of active TB and cost per person at three and ten years (2009
USD), projected life expectancy, lifetime per person costs and cost-
effectiveness measured in incremental cost per year of life saved
(YLS). Life expectancy and costs were discounted at 3% per year
[12]. As suggested by the WHO Commission on Macroeconomics
and Health, an IPT strategy was considered to be ‘‘cost-effective’’
if the incremental cost-effectiveness ratio was less than three times
the Gross Domestic Product (GDP) per capita (for India, GDP per
capita was $980, 3x GDP per capita was $2,940 in 2009 USD
[13,14]Sensitivity analyses were performed to test the stability of
model outputs as parameters were varied.
Model Structure
We utilized the Cost-Effectiveness of Preventing AIDS Compli-
cations (CEPAC)-International model, a computer-based, state
transition model of HIV and TB combined with data on
epidemiologyandtreatmentinIndia.Briefly,individually-simulated,
antiretroviral therapy (ART)-naı ¨ve patients without past history of
TBenteredthemodelandmovedonamonthlycyclethroughhealth
states characterized by chronic HIV infection, active TB, opportu-
nistic diseases, drug toxicity and death. Transition probabilities
between health states were determined by CD4 count, HIV RNA
level, response to ART, and prior history of opportunistic infection
(OI) [15,16]. Incidence of active TB included reactivation of latent
disease and exogenous infection; incidence decreased with use of
ART [17]. According to NACO guidelines, co-trimoxazole was
initiated at a CD4 threshold of ,200 cells/mm
3 [18]. Non-
nucleoside reverse transcriptase inhibitor-based first-line ART was
initiatedataCD4threshold,250 cells/mm
3or,350 cells/mm
3in
the setting of a stage III AIDS-related OI [19]. Patients who failed
first-lineARTwereofferedsecond-lineproteaseinhibitor-containing
therapy [19].
Simulated Strategies
Model strategies were based on the intervention arms of an
open-label, randomized trial completed by the National Institute
for Research in Tuberculosis in Chennai between 2001–2008
comparing the efficacy of two regimens of IPT, a six-month course
of isoniazid plus ethambutol (6EH) and thirty-six month course of
isoniazid (36H) [9]. The primary outcome of the trial was TB
incidence at three-year follow-up. Secondary outcomes were all
cause mortality and adverse events. As there was no placebo arm
in the trial, a ‘‘no IPT’’ strategy was simulated based on previously
published natural history data from the National Institute for
Research in Tuberculosis [3]. To remain conservative, IPT was
assumed to have no benefit after treatment discontinuation,
against drug-resistant TB, and for any patient who did not
complete the full six-or thirty-six month regimens. We assumed
that the risk of re-infection of TB after IPT discontinuation
returned to baseline TB incidence.
To contextualize the findings of 6EH and 36H within current
WHO recommendations for IPT of six months of isoniazid alone,
as well as recent trial results evaluating the use of shorter,
rifamycin-containing regimens for TB prevention in HIV patients,
an additional analysis was performed comparing the incremental
cost-effectiveness of 6EH and 36H with six months of isoniazid
(300 mg) daily (6H), three months of isoniazid (900 mg) plus
rifampin (600 mg) twice weekly (3RH), and three months of
isoniazid (900 mg) plus rifapentine (900 mg) weekly (3RPTH). All
IPT strategies included pyridoxine daily. These IPT regimens
were selected based on WHO guidelines for IPT in resource-
limited settings, as well as recent efficacy data published in
Botswana and South Africa in HIV-infected patients [20,21,22].
Input Data
Cohort Characteristics. Baseline cohort characteristics
were taken from the National Institute for Research in
Tuberculosis trial (Table 1) [9]. The mean age was 30, 63% of
patients were female, and the median CD4 count was 324 cells/
mm
3. Twenty-seven percent of patients met criteria and were
initiated on ART.
HIV and TB Natural History. In the absence of ART,
patients experienced a decline in CD4 count of 3.0–6.4 cells/mm
3
per month as determined by their HIV RNA level [16]. The base
case incidence of active TB among HIV-infected patients without
IPT (6?.90/100 PY) was obtained from previously published data
[3]. The prevalence of isoniazid-resistant TB was 16%; 6% of
patients developed multidrug-resistant (MDR-TB), defined by
resistance to at least isoniazid and rifampin [23]. The incidences of
other OIs, including cryptoccocus, esophageal candidiasis,
Pneumocystis jiroveci pneumonia, toxoplasmosis, Kaposi’s sarcoma,
cytomegalovirus infection, and progressive multifocal
encephalopathy were obtained from the Y. R. Gaitonde Centre
for AIDS Research and Education (YRG CARE) cohort in
Chennai [24,25]. In the absence of data from India, primary data
from Co ˆte d’Ivoire were used for the mortality associated with
AIDS and OIs, and from the US for baseline CD4 decline
[16,26,27,28]. These parameters were tested in sensitivity analysis.
The Efficacy of IPT. The efficacies of the IPT strategies in
the model were based on the TB incidence at three-year follow-up
observed in the intent-to-treat analysis of the 6EH and 36H arms
of the National Institute for Research in Tuberculosis trial. A rate
ratio was calculated by comparing these incidences to the baseline
TB incidence of 6.90 cases/100 PY as assumed for the no IPT
strategy [9]. The incidence of active TB in the 6EH arm was 2.44
cases/100 PY (95% CI 1.42–3.46), resulting in an incidence rate
ratio for the 6EH strategy of 0.35 compared to no IPT [9]. The
incidence of active TB in the 36H arm was 1.55 cases/100 PY
(95% CI 0.73–2.36), resulting in an incidence rate ratio for the
36H strategy of 0.22 compared to no IPT [9]. Projections were
based on the assumption that the difference between the point
estimates of efficacy for 6EH and 36H were significant. Because
this difference did not reach significance in the trial, likely due to a
low event rate and study power, sensitivity analyses were
performed to examine the optimal scenarios in which the 36H
strategy was cost-effective compared to the 6EH strategy.
In the absence of data from India, and the modeled trial
specifically, the efficacy of alternative IPT strategies in HIV-
infected patients was estimated from trials performed in HIV-
infected persons in sub-Saharan Africa. The relative incidence of
Cost-Effectiveness of TB Preventive Therapy
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trial data from Botswana [21]. This study was selected given a
similar randomized trial structure as that performed in India in the
post-ART era. A rate ratio comparing this incidence with the
baseline incidence of TB from sub-Saharan Africa, adjusted by the
availability of ART was calculated to be 0.39. The efficacy of 3RH
and 3RPTH was similarly calculated using data from South Africa
and both found to be 0.32 [20,29].
Active TB Treatment. Active TB in patients who had not
received IPT was treated with a Category I regimen, consisting of
initiation with isoniazid, rifampin, pyrazinamide, and ethambutol
thriceweeklyfortwomonths,followedbyisoniazidandrifampinfor
four months as defined by the Revised National TB Control
Programme (RNTCP) of India [7]. In patients who received IPT,
cases of active TB were considered treatment failures and were
treatedwithaCategoryIIregimen,consistingofisoniazid,rifampin,
pyrazinamide, ethambutol thrice-weekly for eight months, and the
addition of an injectable aminoglycoside thrice-weekly for the first
two months [7]. Of the patients with isoniazid-resistant, non MDR-
TB, 18% were presumed to fail Category I treatment and required
Category II treatment [30]. Patients with MDR-TB sequentially
failedCategoryIandCategoryIItreatment, andweresubsequently
treated with an aminoglycoside, a quinolone, ethambutol,
ethionamide and pyrazinamide for twenty-four months [7].
HIV Treatment. First-line ART consisted of stavudine,
lamivudine, and nevirapine as recommended by NACO [19].
ART efficacy was based on data from the Therapeutics Research,
Education, and AIDS Training in Asia (TREAT ASIA), and the
Antiretroviral Therapy in Low-Income Countries (ART-LINC)
cohorts, which reported 48-week virologic suppression of 73% and
mean CD4 count increase of 148 cells/mm
3 at 24 weeks [31,32].
Second-line therapy consisted of tenofovir, lamivudine, and
lopinovir/ritonavir [19]. In the absence of efficacy data for
protease inhibitor-based regimens in India, the efficacy of second-
line therapy was assumed to be similar to first line-therapy. This
assumption was tested in sensitivity analysis.
Toxicity. The likelihood of toxicity associated with 6EH and
36H was obtained from the National Institute for Research in
Tuberculosis trial. Minor toxicity, defined as rash, elevated
aminotransferases, and mild neuropathy, did not change
duration of treatment or treatment efficacy, and occurred with a
probability of 0.03 in the 6EH and 36H strategies [9]. Major
toxicity, defined as severe hepatitis or severe neuropathy leading to
permanent discontinuation of treatment occurred in two patients
in the 36H arm. As treatment was not permanently discontinued
in any patients in the 6EH arm, we calculated a pooled probability
of major toxicity of 0.0029 for both strategies [9]. There were no
episodes of fatal hepatitis in either the 6EH or 36H strategies. The
toxicities of alternate strategies of IPT were obtained from
published data (Table 2). Since the likelihood of minor toxicity
of 6H was not reported in the Botswana trial, we assumed it to be
the same as 6EH. Major toxicity leading to discontinuation of the
drug occurred in 1.4% of patients, with fatal hepatitis occurring in
0.1% of patients [21]. Drug discontinuation due to major toxicity
or pregnancy in the 3RH and 3RPTH strategies occurred in 3.8%
and 1.8% of patients, respectively [20].
Table 1. Baseline cohort characteristics, TB and HIV natural history, HIV treatment parameters.
Parameter Base Case Value Range for Sensitivity Analysis References
Cohort characteristics
Mean age (years), SD 30, 7 [9]
Gender (% female) 63 [9]
Median CD4 (cells/mm
3), IQR 324, 200–506 100–500 [9]
% receiving ART 27 [9]
TB Natural History
TB Incidence/100 PY 6.90 5.0–10.0 [3,9,24]
Drug resistant TB
All isoniazid-resistant TB (%) 16% 8%–64% [23]
MDR-TB (%) 6% 3%–24% [23]
Probability of death with TB, range by CD4 strata
a
Non-MDR TB 0–0.50 0–0.74 [27,28,56]
MDR-TB 0–0.56 0–0.84 [27,28,56]
Natural history of HIV
Monthly CD4 decline (cells/mm
3) by viral load
.30,000 copies/ml 6.4 3.2–12.8 [55]
10,001–30,000 copies/ml 5.4 2.7–10.8 [55]
3,001–10,000 copies/ml 4.6 2.3–9.2 [55]
501–3,000 copies/ml 3.7 1.85–7.4 [55]
,= 500 copies/ml 3.0 1.5–6.0 [55]
Efficacy of ART for first and second line ART
HIV RNA suppression at 48 weeks (%) 73 66–80 [32]
CD4 cell increase at 24 weeks (cells/mm
3) 148 133–163 [31]
SD: Standard deviation; IQR: Interquartile range; TB: Tuberculosis;P Y : Person-Years; MDR: Multidrug-resistant; ART: Antiretroviral therapy.
aProbability of death within 6 months after active TB.
doi:10.1371/journal.pone.0036001.t001
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medication costs, the costs of pre-screening for active TB
(symptom screen and exam as recommended by the WHO),
quarterly clinic visits, and liver function tests every six months
(Table 3) [33,34,35]. Costs for Category I, Category II, and MDR-
TB treatment included previously published costs of acute disease,
medication costs, and directly observed therapy (DOT) [8,34,35].
Costs of ART were obtained from NACO [36]. Resource
utilization including mean outpatient and inpatient days for
routine HIV care, laboratory monitoring including CD4 count,
treatment of opportunistic infection, and toxicity were derived
from YRG CARE [8,33,37].
Sensitivity Analysis
Efficacies of 6EH and 36H regimens were varied within the
bounds of the 95% confidence interval obtained from the trial
analysis [9]. The probability of IPT-related toxicity and associated
probability of death from fatal hepatitis were varied in each
regimen independently from 0–20% based on the literature [38].
Adherence to IPT was examined by varying the percent of the
cohort achieving regimen completion. An ART starting criterio
n#350 cells/mm
3 was examined given new WHO guidelines for
ART initiation [39]. The costs of IPT and active TB treatment
were varied to reflect estimates in the literature, as well as inclusion
of intensified case-finding using AFB smear, culture and chest
radiograph [40,41,42,43]. The baseline incidence of TB, preva-
lence of drug-resistant TB, mean CD4 count at model entry, rates
of CD4 decline, and CD4-specific mortality were also varied to
examine the effect of population heterogeneity. Multi-way analyses
of parameters were examined to assess their policy impact.
Results
Base Case Analysis and Model Validation
At three-year follow-up, model projections for TB incidences in
the no IPT, 6EH, and 36H strategies were 4.54, 2.23, and 1.74
cases/100 PY (Table 4). The estimates lay within the 95%
confidence interval of the trial results [9]. Rates for all strategies
trended towards convergence at ten years. At three-year follow-up,
per-person costs were $680, $720, and $770 in the no IPT, 6EH
and 36H strategies, and at ten-year follow-up, per-person costs
were $2,740, $2,820, and $2,870.
In the absence of IPT, the projected discounted life expectancy
was 136.1 months, with a discounted mean per person lifetime cost
of $5,630 (Table 5). 6EH increased the discounted life expectancy
to 136.9 months at an additional cost of $101 per person, resulting
in an incremental cost-effectiveness ratio of $1,490/YLS. The life
expectancy with 36H was 137.1 months at an additional cost of
$55 compared to 6EH, resulting in an incremental cost-
effectiveness ratio of $3,120/YLS.
Sensitivity Analyses: 6EH Compared to No IPT
In one-way sensitivity analysis, 6EH remained cost-effective
compared to no IPT (with an incremental cost-effectiveness ratio
Table 2. Efficacy and toxicity of IPT.
Parameter Base Case Value Range for Sensitivity Analysis Ref.
Efficacy of IPT, RR
a 95% CI
6EH 0.35 0.21–0.5 [9]
36H 0.22 0.11–0.34 [9]
6H 0.39 0.20–0.60 [21]
3RH 0.32 0.16–0.48 [20]
3RPTH 0.32 0.16–0.48 [20]
Adherence
Regimen completion IPT (%) 100 40–100 [9]
Toxicity
Probability of IPT associated minor toxicity
6EH 0.03 0–0.20 [9]
36H 0.03 0–0.20 [9]
6H 0.03 0–0.20 Assumed
3RH 0.07 0–0.20 [20]
3RPTH 0.06 0–0.20 [20]
Probability of IPT associated major toxicity
b
6EH 0.0029 0–0.20 [9]
36H 0.0029 0–0.20 [9]
6H 0.0140 0–0.20 [50]
3RH 0.0380 0–0.20 [20]
3RPTH 0.0180 0–0.20 [20]
Probability of fatal toxicity 0–0.001 0–0.20 [9]
IPT: Isoniazid-based Preventive Therapy; RR: Rate Ratio; 6EH: Six-month regimen of isoniazid plus ethambutol; 36H: Three-year regimen of isoniazid; 3RH: Three-
month regimen of isoniazid plus rifampin; 3RPTH: Three-month regimen of isoniazid plus rifapentine.
aEfficacy defined by rate ratio of TB incidence in the 6EH and 36H IPT regimens compared to no IPT at three year follow-up.
bWithin first month of treatment.
doi:10.1371/journal.pone.0036001.t002
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when the mean CD4 count was ,490 cells/mm
3 at baseline,
when at least 55% of the total cohort completed the 6EH regimen,
and when the cost of the 6EH regimen was increased to $130
reflecting intensified case-finding with three AFB smears and
cultures plus chest radiograph at initial screening, as well as two
smears and cultures plus chest radiograph every six months
thereafter (Figure 1). When the efficacy of 6EH was varied
between the bounds of the 95% confidence interval of the point
estimates observed in the trial, the incremental cost-effectiveness
ratios ranged from $1,360/YLS to $1,790/YLS. The incremental
cost-effectiveness ratios remained stable with wide variations in
other parameters, including increasing the probability of major
toxicity to 20%, increasing the probability of death from major
toxicity to 20%, increasing the cost of active TB by 500%, tripling
the prevalence of isoniazid-resistant TB to 48% (with prevalence of
MDR-TB increased to 18%), ranging the overall incidence of TB
from 5 to 10 cases/100 PY, and expanding the CD4 ART
initiation to #350, cells/mm
3. Results were stable with wide
variation in rates of CD4 decline, CD4-specific mortality, and
ART efficacy.
Table 3. Selected cost parameters.
Parameter Base Case Value Range for Sensitivity Analysis Ref.
Costs (2009 USD)
Chest radiograph 1 0.30–3 [35]
TB sputum stain and culture 17 6–50 [33,35]
Liver function test 9 3–27 [33]
DOT visit 1 0.30–3 [35]
IPT Regimens
a
Total 6EH course 40 19–133 [33,34,35]
Total 36H course 90 47–363 [33,34,35]
Total 6H course 20 [33,34,35]
Total 3RH course 25 [33,34,35]
Total 3RPTH course 180 [33,34,35,57]
Active TB treatment
b
Drug-sensitive TB
c 50 41–300 [8,34,35]
INH-resistant, non-MDR TB
d 140 113–906 [8,34,35]
MDR-TB
e 2,630 2,105–16,842 [8,34,35]
First-line ART (NNRTI-based), monthly 9 8–10 [36]
Second-line ART (PI-based), monthly 55 50–60 [36]
USD: US Dollars; TB: Tuberculosis; DOT: Directly Observed Therapy; 6EH: Six-month regimen of isoniazid plus ethambutol; 36H: Three-year regimen of isoniazid; 3RH:
Three-month regimen of isoniazid plus rifampin; 3RPTH: Three-month regimen of isoniazid plus rifapentine; MDR: multidrug-resistant; ART: Antiretroviral Therapy;
NNRTI: Non-nucleoside reverse transcriptase inhibitor; PI: Protease inhibitor; 3RPTH: Three-month regimen of isoniazid plus rifapentine.
aIncludes clinic visits, TB symptom screening quarterly, liver function tests every six months, and medications.
bIncludes costs of acute presentation of TB (including inpatient and outpatient visits), plus TB treatment plus DOT.
cCategory I (two-months intensive phase with isoniazid, rifampin, pyrazinamide, and ethambutol thrice-weekly, then four-months continuation phase with isoniazid and
rifampin thrice-weekly) and DOT.
dCategory I failure, followed by Category II treatment (three-months intensive phase with isoniazid, rifampin, pyrazinamide, and ethambutol thrice-weekly, with first two
months including streptomycin thrice-weekly, then five-month continuation phase with isoniazid, rifampin and ethambutol thrice-weekly) and DOT.
eCategory I and II failure, followed by MDRTB treatment (six-month intensive phase with streptomycin, ofloxacin, ethambutol, ethionamide, and pyrazinamide daily,
followed by an eighteen-month of continuation phase with ofloxacin, ethambutol, ethionamide, and pyrazinamide daily) and DOT.
doi:10.1371/journal.pone.0036001.t003
Table 4. Model validation and 10-year outcomes for TB incidence and cost of 6EH and 36H compared to no IPT.
Model Validation: 3 Year Outcomes Model Projections: 10 Year Outcomes
Trial Data [9] Model Projections
Strategy
TB cases per 100 PY
(95% CI)
TB cases per
100 PY
Discounted mean per person
cost, 2009 USD TB cases per 100 PY
Discounted mean per person
cost, 2009 USD
No IPT n/a 4.54 680 4.47 2,740
6EH 2.44 (1.42–3.46) 2.23 720 3.62 2,820
36H 1.55 (0.73–2.36) 1.74 770 3.44 2,870
TB: Tuberculosis; PY: Person-Years; USD: US Dollars; IPT: Isoniazid-based TB preventive therapy; 6EH: Six-month regimen of isoniazid plus ethambutol; 36H: Three-
year regimen of isoniazid.
doi:10.1371/journal.pone.0036001.t004
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effectiveness of 6EH remained #$2,940/YLS under the most
optimal assumption of efficacy (RR=0.21, representing the lower
bound of the 95% confidence interval for the point estimate of
efficacy in the trial) when the probability of toxicity was as high as
20% and at least 56% of the cohort completed the regimen
(Figure 2). Using the least optimal assumption for efficacy
(RR=0.50, representing the upper bound of the 95% confidence
interval), the regimen remained cost-effective if the probability of
major toxicity was less than 10% and at least 69% of the cohort
completed the regimen.
Sensitivity Analyses: 36H Compared to 6EH
Assuming a significant difference between the efficacy of 36H
and 6EH, the impact of the mean CD4 count, regimen cost, and
percent cohort completion had similar impact on cost-effectiveness
when parameters were individually varied (Figure 3). The 36H
regimen was cost-effective compared to 6EH when the cost was
reduced to $70, the median CD4 was decreased to 300 cells/mm
3,
and when the prevalence of INH-resistant TB was decreased to
8%. A multi-way sensitivity analysis was performed to examine a
best case scenario in which the point estimate for the 36H regimen
was significant, the cost of the regimens was reduced to $20 by
Table 5. Incremental cost-effectiveness of TB preventive therapy for HIV-infected individuals in India.
Strategy
Discounted mean per person lifetime cost,
2009 USD
Discounted mean person life expectancy,
months (undiscounted) Incremental Cost-effectiveness ratio, $/YLS
No IPT 5,630 136.1 (184.5) –
6EH 5,730 136.9 (185.6) 1,490
36H 5,780 137.1 (185.8) 3,120
TB: Tuberculosis; PY: Person-Years; USD: US Dollars; IPT: Isoniazid-based TB preventive therapy; 6EH: Six-month regimen of isoniazid plus ethambutol; 36H: Three-
year regimen of isoniazid; YLS: Year of life saved.
doi:10.1371/journal.pone.0036001.t005
Figure 1. Tornado diagram of one-way sensitivity analyses comparing the 6EH regimen to no IPT. Selected model parameters are listed
on the vertical axis, with the range examined in sensitivity analyses listed in parentheses. The length of the horizontal bar demonstrates the impact of
changes in the parameter values on the incremental cost-effectiveness ratios for the 6EH regimen compared to no IPT. The solid vertical line indicates
the incremental cost-effectiveness ratio estimate ($1,490/YLS) of the base case, and the dashed vertical line indicates the suggested cost-effectiveness
threshold ratio of $2,940/YLS (3x GDP India). Values in white in the center of the bars indicate the threshold value of each parameter at which the
cost-effectiveness ratio for 6 months of IPT compared to no IPT is equal to $2,940/YLS. For example, Adherence to the 6EH regimen was varied from
40%–100%. The incremental cost-effectiveness ratio of 6EH compared to no IPT was less than or equal to $2,940/YLS (i.e. cost-effective by
international standards) when percent cohort completion was as low as 55%. 6EH: Six-month regimen of isoniazid plus ethambutol, IPT: Isoniazid-
based Preventive Therapy, YLS: Year of Life Saved, GDP: Gross Domestic Product.
doi:10.1371/journal.pone.0036001.g001
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would be included in routine HIV costs when HIV and TB care
were co-localized) and ART was initiated at a CD4 count
#350 cells/mm
3. In this scenario, the 36H regimen was more
cost-effective than the 6H regimen, with an incremental cost-
effectiveness ratio, compared to no IPT, of $1,130/YLS.
Expanded IPT Strategies
When additional IPT strategies were considered, 6H resulted in
a projected life expectancy of 136.9, with a mean, discounted per
person lifetime cost of $5,700, whereas 3RH increased projected
life expectancy by 0.03 months at a per person lifetime cost of
$5,710 (Table 6). The 6EH strategy was eliminated by extended
dominance (less cost-effective than other more effective strategies)
due to the increased per person lifetime cost without associated
mortality benefit relative the 3RH regimen. When the efficacy of
the 6EH regimen was increased to represent the lower bound of
the 95% confidence interval for this regimen (TB incidence rate
ratio=0.21), as observed in the trial setting, the strategy was no
longer dominated, and had an incremental cost-effectiveness ratio
of $2,440/YLS (data not shown).
When compared to the 3RH regimen, the incremental cost-
effectiveness of 36H was $4,290/YLS. Compared to 36H, per
person lifetime cost increased by $80 for the 3RPTH regimen and
was associated with decreased life expectancy.
Discussion
Our analysis demonstrated that a six-month course of isoniazid-
based preventive therapy for HIV-infected individuals decreased
TB incidence, increased overall life expectancy and was cost-
effective in India. These findings were robust across wide
variations in parameters including adherence, prevalence of
drug-resistant TB, drug toxicity, and costs. The thirty-six month
regimen may be considered more cost-effective than the six month
regimen in the best case scenario when efficacy was significantly
greater than the six-month regimen, only marginal costs of IPT
medications were considered in the case of co-localized TB/HIV
care, and ART was initiated earlier.
Several recent trials have examined various IPT regimens for
HIV-infected individuals in resource-limited settings, including six
months versus continuous isoniazid in Botswana, and short courses
of rifampin and rifapentine containing regimens in South Africa
[20,21,44]. Compared to 6H and 3RH, the 6EH regimen offered
comparable efficacy at increased cost. When the efficacy of 6EH
was varied within the 95% confidence interval of trial observa-
tions, the regimen became cost-effective, suggesting marginal
differences in the clinical and economic impact of these regimens.
3RPTH, while conferring similar efficacy, was considerably more
costly, and was therefore not found to be cost-effective in
comparison to other regimens. While improved adherence and
toxicity associated with four months of rifampin alone has been
Figure 2. Multi-way sensitivity analysis of 6EH major toxicity, regimen completion, and efficacy. Major toxicity associated with 6EH,
percent cohort completion of the regimen, and efficacy of the regimen are varied simultaneously. The solid line represents the point estimate of
efficacy for the 6EH regimen as observed in the trial, i.e. a rate ratio of tuberculosis incidence of 0.35 compared to no IPT, varied over a range of
percent cohort completion of the regimen and probability of major toxicity. The shaded area to the right of the line represents all values at which the
6EH regimen is cost-effective, based on 3x the GDP per capita of India. The hatched line represents the leftwards shift in the boundary of cost-
effectiveness when the rate ratio of TB incidence with 6EH is 0.21 compared to no IPT, as calculated from the lower bound of the 95% confidence
interval of the trial. The dotted line represents the rightwards shift in the boundary of cost-effectiveness when the relative risk of TB with 6EH is 0.50
compared to no IPT, as calculated from the upper bound of the 95% confidence interval of the trial. The diamond in the lower right corner represents
the base case, trial-based scenario, where percent cohort completion is 100% and the probability of major toxicity is 0.0029. 6EH: Six-month regimen
of isoniazid plus ethambutol, IPT: Isoniazid-based Preventive Therapy, GDP: Gross Domestic Product.
doi:10.1371/journal.pone.0036001.g002
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current analysis as efficacy for the regimen has not yet been
established in large scale clinical trials [45]. Additionally, concern
for the theoretical risk of rifampin resistance in the setting of
monotherapy has been raised [46].
The study differs from prior cost-effectiveness analyses of IPT in
HIV-infected patients given greater availability of antiretroviral
therapy [43,47,48]. In an analysis by Bell et. al. in the pre-ART
era, six months isoniazid extended life expectancy from 7.79 to
8.37 years, and increased cost per person from $25.30 to $38.31
with an incremental cost-effectiveness ratio of $114/QALY [47].
Other pre-ART studies in Zambia and Cambodia found IPT to be
cost-saving [43,48]. In this analysis ART increased CD4 counts,
thereby reducing the risk of TB and related mortality independent
of IPT. This attenuation of the absolute IPT efficacy, coupled with
the cost of chronic HIV care explains the findings of longer life
Figure 3. Tornado diagram of one-way sensitivity analyses comparing the 36H regimen to the 6EH regimen. Selected model
parameters are listed on the vertical axis, with the range examined in sensitivity analyses listed in parentheses. The horizontal axis demonstrates the
impact of changes in the parameter values on the incremental cost-effectiveness ratios for the 36H regimen compared to 6EH regimen. The solid
vertical line indicates the incremental cost-effectiveness ratio estimate ($3,120/YLS) of the base case, and the dashed vertical line indicates the
suggested cost-effectiveness threshold ratio of $2,940/YLS (3x GDP India). Values in white in the center of the bars indicate the threshold value of
each parameter at which the cost-effectiveness ratio for 36H compared to 6EH is equal to $2,940/YLS. For example, a total cost of $90 for the 36H
regimen was assumed in the base case. The incremental cost-effectiveness ratio of 36H compared to 6EH was less than or equal to $2,940/YLS (i.e.
cost-effective by international standards) when the cost of 36H was less than $70. 36H: Thirty-six-month regime of isoniazid, 6EH: Six-month
regimen of isoniazid plus ethambutol, YLS: Year of Life Saved, GDP: Gross Domestic Product.
doi:10.1371/journal.pone.0036001.g003
Table 6. Incremental cost-effectiveness of additional strategies for TB preventive therapy.
Strategy
Discounted mean per person lifetime
cost, 2009 USD
Discounted mean person life
expectancy, months
Incremental cost-effectiveness
ratio, $/YLS*
No IPT 5,630 136.1 –
6H 5,700 136.9 1,140
3RH 5,710 136.9 1,610
6EH 5,730 136.9 Dominated
a
36H 5,780 137.1 4,290
3RPTH 5,860 136.9 Dominated
b
TB: Tuberculosis; USD: US Dollars; YLS: Years of life saved: IPT: Isoniazid-based preventive therapy; 6H: Six-month regimen of isoniazid; 3RH: Three-month regimen of
isoniazid plus rifampin; 6EH: Six-month regimen of isoniazid plus ethambutol; 36H: Three-year regimen of isoniazid; 3RPTH: Three-month regimen of isoniazid plus
rifapentine.
*The incremental cost-effectiveness ratios may not exactly match the ratios of lifetime cost and life expectancy reported in the table due to rounding.
aWeakly dominated (more expensive but confers less clinical benefit than some combination of other strategies) [12].
bStrongly dominated (more expensive but confers less clinical benefit than some other strategy) [12].
doi:10.1371/journal.pone.0036001.t006
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ratio. The six-month regimen remained cost-effective when the
CD4 threshold for ART initiation was increased to #350 cells/
mm
3 suggesting that IPT remained a good value for money as
countries expand access to ART, and could further support IPT
given recent studies examining the complementary effects of IPT
and ART [17].
Critics of IPT cite the potential increased risk of hepatotoxicity
in the setting of expanded ART [49]. In a recent clinical trial in
Botswana of IPT in HIV-infected patients, 1.1% of subjects
developed severe hepatitis, of whom 5% died [50]. In sensitivity
analysis, six months of IPT remained cost-effective well within this
range of toxicity.
Risk of undiagnosed TB at time of IPT initiation, poor
adherence, and drug-resistance are other cited barriers to the
success of IPT [49,51,52]. In the current analysis, six months of
IPT remained cost-effective when the cost of intensified case-
finding, defined by TB smear and culture times three plus chest
radiograph at IPT initiation, and smear and culture times two plus
chest radiograph every six months thereafter were included. In
regards to adherence, six months of IPT remained cost-effective
even if 45% of the population did not complete the regimen. This
is consistent with a cohort study performed in South Africa where
adherence as low as 59% conferred a 27% reduction in the
incidence of TB [53]. Shorter courses of rifamycin-containing IPT
may abrogate this issue further still given higher rates of adherence
in these regimens [20,44]. When the prevalence of drug-resistant
TB was increased to 48%, six months of IPT remained cost-
effective. In most developing countries, including India, the
prevalence of primary isoniazid resistance varies from 5 to 27%
[54].
These findings should be interpreted within the context of
certain limitations. Efficacy calculations were derived comparing
trial data to natural history data for TB incidence as there was no
placebo arm in recent trials. This is a benefit of model-based
studies which can compare strategies that would otherwise be
unethical to evaluate in a trial. The difference in efficacy of 36H
compared to 6EH did not reach statistical significance in the trial.
Projections of the 36H regimen suggest that it may be cost-
effective as compared to the 6EH regimen in the best case
scenario. Several data sources, including the efficacy of additional
IPT regimens, mortality associated with AIDS and OI from Co ˆte
d’Ivoire were used to populate the model when Indian data were
not available. These assumptions were extensively tested in
sensitivity analysis. Previous studies have found greater IPT
efficacy in patients with positive tuberculin skin testing [38]. This
strategy was not examined as TB incidence was not significantly
different when stratified by skin test ,5 mm and $ 5 mm in either
arms of the National Institute for Research in Tuberculosis trial
[9]. Finally, secondary TB transmission was not modeled, likely
underestimating the benefits of IPT given prevention of TB
transmission at no additional cost.
The magnitude of TB-associated morbidity and mortality in
HIV-infected patients has prompted the government of India to
enhance interventions addressing both diseases [7]. The safety and
efficacy of isoniazid-based preventive therapy has been demon-
strated in this setting [9]. This analysis shows that a three-month
course of isoniazid plus rifampin and a six-month of isoniazid
alone both decrease TB incidence and are similarly cost-effective
by WHO criteria. Inclusion of isoniazid-based therapy as part of
HIV care represents a critical and cost-effective opportunity to
enhance TB control and improve outcomes for HIV-infected
patients.
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